A Platform for Automated CRISPR-Based Microbial Genome Engineering
Discover how you can design and generate genomic edits to optimize heterologous protein expression and activity in E. coli. (Source: The Scientist)
Source: The Scientist - January 25, 2022 Category: Science Tags: The Marketplace Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment. “Treating very youn...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news
Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment. “Treating very youn...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news
What Are Common Gastrointestinal Polyposes in Children?
Discussion
Bloody stools or blood in the diaper is a relatively common complaint in general pediatrics. For most patients it is often a minor concern. Commonly it is a transient problem (e.g. rectal fissure caused by constipation or trauma) or often not blood (e.g. urate crystals in the diaper, food, menses, etc.). Real blood does occur with an identifiable cause such as long distance running or heavy exercise, or milk protein allergy/sensitivity that improves with a milk-restricted diet. Many more serious causes are associated with heavier or more recalcitrant bleeding, increased defecation, abdominal pain, poor eating an...
Source: PediatricEducation.org - January 24, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Fosfomycin Not Noninferior to Comparators for Bacteremic UTI
FRIDAY, Jan. 14, 2022 -- For patients with bacteremic urinary tract infections (bUTIs) due to multidrug-resistant (MDR) Escherichia coli, fosfomycin is not noninferior to comparators, with an increased rate of adverse event-related discontinuations,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2022 Category: Pharmaceuticals Source Type: news
Nasal spray made with nasty gut bug to stop flu
The spray contains a flu vaccine mixed with the Escherichia coli (E. coli) bacterium, which can lead to severe stomach cramps, diarrhoea and vomiting. (Source: the Mail online | Health)
Source: the Mail online | Health - January 10, 2022 Category: Consumer Health News Source Type: news
Meat Company Recalls 28,000 Pounds of Ground Beef
A meat company is recalling 28,356 pounds of ground beef that may be contaminated with an E. coli strain known as O157:H7. (Source: WebMD Health)
Source: WebMD Health - January 10, 2022 Category: Consumer Health News Source Type: news
Packaged Salads Tied to E. Coli Outbreak in Six States
MONDAY, Jan. 3, 2022 -- More than a dozen people have been infected by a strain of Escherichia coli in six U.S. states, health officials report.
The U.S. Centers for Disease Control and Prevention issued a food safety alert linking the outbreak to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2022 Category: Pharmaceuticals Source Type: news
Packaged Salads Tied to E. Coli Outbreak in 6 States
MONDAY, Jan. 3, 2022 -- Check your packaged salad greens: More than a dozen people have been infected by a strain of E. coli in six U.S. states, health officials report.
The U.S. Centers for Disease Control and Prevention issued a food safety alert... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2022 Category: General Medicine Source Type: news
Effectiveness and real-world materials compatibility of a novel hydrogen peroxide disinfectant cleaner.
A novel 4% hydrogen peroxide disinfectant was effective against methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile spores, carbapenem-resistant Escherichia coli, and 2 strains of Candida auris. In laboratory testing, a sodium hypochlorite disinfectant caused fading and loss of pliability of a hospital mattress, but the hydrogen peroxide disinfectant did not. These findings suggest that the hydrogen peroxide-based disinfectant may be a useful addition to the sporicidal disinfectant products available for use in healthcare settings. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 14, 2021 Category: Consumer Health News Source Type: news
Consumer Health: Understanding the flu and why you need to get a flu shot
National Influenza Vaccination Week will be observed Dec. 5 –11, which makes this a good time to learn more about the flu and why you need to get a flu shot. What many people call the flu is actually viral gastroenteritis, or stomach flu, which is characterized by diarrhea, nausea, and abdominal cramps and pain. Influenza is the true flu. It's a viral infection that attacks your respiratory system, including your nose, throat and lungs. At first, flu… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 8, 2021 Category: Databases & Libraries Source Type: news
Latest Phase 3 Data for First-in-Class TREMFYA ® (guselkumab) Demonstrates Significant and Durable Improvement in Signs and Symptoms of Active Psoriatic Arthritis while Maintaining its Safety Profile in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, December 3, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new TREMFYA® (guselkumab) efficacy and safety data from the Phase 3b COSMOS trial published in Annals of the Rheumatic Diseases (ARD), evaluating this selective interleukin (IL)-23 inhibitor in adults with active psoriatic arthritis (PsA) who demonstrated inadequate efficacy or intolerance to tumor necrosis factor inhibition (TNFi).1 Results showed significantly higher proportions of patients treated with TREMFYA had improvement in joint signs and symptoms and complete skin clearance versus placeb...
Source: Johnson and Johnson - December 3, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Adjunctive benefits of systemic metronidazole on non-surgical treatment of peri-implantitis. A randomized placebo-controlled clinical trial
Conclusions: The use of systemic metronidazole as an adjunct to non-surgical treatment of peri-implantitis resulted in significant additional improvements in clinical, radiographic, and microbiological parameters after 12 months of follow-up. This study is registered in ClinicalTrials.gov (NCT03564301). (Source: Dental Technology Blog)
Source: Dental Technology Blog - November 30, 2021 Category: Dentistry Source Type: news
